Clinical Trials Directory

Trials / Completed

CompletedNCT03525080

Comparison of 6-fluoro-[18F]-L-dihydroxyphenylalanine (18F-DOPA) Positron Emission Tomography (PET) and Multiparametric Resonance Magnetic Imagery (RMI) in Initial Exploration of Glial Tumors

Diagnostic Assessment Study, Single Site and Prospective, comparing18F-DOPA PET and Multiparametric RMI in Initial Exploration of Diffuse Glial Tumors

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
16 (actual)
Sponsor
Center Eugene Marquis · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

For patient having a brain tumor, RMI is the standard exam for tumor characterization and determines initial surgery. The aim of this study is to assess if PET could provide additional information that could have an impact on surgery (indication and planification)

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTPET imageryEvery patients will have a PET imagery in addition to standard MRI

Timeline

Start date
2018-06-12
Primary completion
2019-09-11
Completion
2019-09-11
First posted
2018-05-15
Last updated
2020-01-27

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT03525080. Inclusion in this directory is not an endorsement.

Comparison of 6-fluoro-[18F]-L-dihydroxyphenylalanine (18F-DOPA) Positron Emission Tomography (PET) and Multiparametric (NCT03525080) · Clinical Trials Directory